Kiniksa Pharmaceuticals International, plc Deferred Revenue Recognized
Kiniksa Pharmaceuticals International, plc (KNSA) reported Deferred Revenue Recognized of -$37.08 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-02-25
- Kiniksa Pharmaceuticals International, plc contract with customer, liability, revenue recognized for fiscal 2023 was -$37.08M.
- Kiniksa Pharmaceuticals International, plc contract with customer, liability, revenue recognized for fiscal 2022 was -$21.95M.
| Period end | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|
| 2023-12-31 | -$37.08M 10-K · filed 2025-02-25 |
| 2022-12-31 | -$21.95M 10-K · filed 2024-02-28 |